Abstract P5-18-21: A Phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for ErbB2-overexpressing metastatic breast cancer (MBC)

W Janni(University Hospital Ulm), C Papadimitriou(Hôpital René Huguenin), Francisco Sapunar(Hôpital René Huguenin), Elżbieta Starosławska(Lublin Oncology Center), Tomasz Sarosiek, Michelle De Silvio(Hôpital René Huguenin), Christian Caglevic, E. Brain(Hôpital René Huguenin), Bogusława Karaszewska(State University of Applied Sciences in Konin), Kathryn Jane Briggs(GlaxoSmithKline (United Kingdom)), Christoph Salat(Praxis für Hämatologie und Onkologie), Joanna Pikiel(Chemotherapy Foundation), Piotr Potemski(Copernicus Memorial Hospital)
Cancer Research
December 1, 2012
10.1158/0008-5472.sabcs12-p5-18-21
Cited by 2

Related Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
|New England Journal of Medicine|2019|1.4k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k